Outcomes of oral vinorelbine in progressive desmoid fibromatosis-response

Olivier Mir; Charles Honoré; Ali N. Chamseddine; Matthieu Faron; Leila Haddag-Miliani; Arnaud Bayle; Axel Le Cesne

doi:10.1158/1078-0432.CCR-21-0041

Outcomes of oral vinorelbine in progressive desmoid fibromatosis-response

Olivier Mir, Charles Honoré, Ali N. Chamseddine, Matthieu Faron, Leila Haddag-Miliani, Arnaud Bayle, Axel Le Cesne

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	2120
Nombre de pages	1
journal	Clinical Cancer Research
Volume	27
Numéro de publication	7
Les DOIs	https://doi.org/10.1158/1078-0432.CCR-21-0041
état	Publié - 1 avr. 2021

Accès au document

10.1158/1078-0432.CCR-21-0041

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{6c24a15076b64b85ae631fc461d5ea75,

title = "Outcomes of oral vinorelbine in progressive desmoid fibromatosis-response",

author = "Olivier Mir and Charles Honor{\'e} and Chamseddine, {Ali N.} and Matthieu Faron and Leila Haddag-Miliani and Arnaud Bayle and {Le Cesne}, Axel",

note = "Funding Information: O. Mir reported personal fees from Amgen, Blueprint Medicines, Eli Lilly, Ipsen, Lundbeck, Pfizer, Roche, and Servier outside the submitted work. M. Faron reported personal fees from HRA Pharma and other from IPSEN and Novartis outside the submitted work. A. Bayle reported as part of the Drug Development Department (DITEP), principal/subinvestigator of clinical trials for AbbVie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, arGEN-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, BBB Technologies BV, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Therapeutics, GamaMabs, Genentech, GlaxoSmithKline, H3 Biomedicine, Hoffmann La Roche Ag, ImCheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, and Xencor, research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Onxeo, Pfizer, Roche, and Sanofi, and nonfinancial support (drug supplied) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Medimmune, Merck, NH TherAguiX, Onxeo, Pfizer, and Roche. A. Le Cesne reported personal fees from PharmaMar and Bayer outside the submitted work. No disclosures were reported by the other authors.",

year = "2021",

month = apr,

day = "1",

doi = "10.1158/1078-0432.CCR-21-0041",

language = "English",

volume = "27",

pages = "2120",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "7",

}

TY - JOUR

T1 - Outcomes of oral vinorelbine in progressive desmoid fibromatosis-response

AU - Mir, Olivier

AU - Honoré, Charles

AU - Chamseddine, Ali N.

AU - Faron, Matthieu

AU - Haddag-Miliani, Leila

AU - Bayle, Arnaud

AU - Le Cesne, Axel

N1 - Funding Information: O. Mir reported personal fees from Amgen, Blueprint Medicines, Eli Lilly, Ipsen, Lundbeck, Pfizer, Roche, and Servier outside the submitted work. M. Faron reported personal fees from HRA Pharma and other from IPSEN and Novartis outside the submitted work. A. Bayle reported as part of the Drug Development Department (DITEP), principal/subinvestigator of clinical trials for AbbVie, Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, arGEN-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International Ltd, Bayer Healthcare Ag, BBB Technologies BV, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol Myers Squibb, Ca, Celgene Corporation, Chugai Pharmaceutical Co, Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm, Eisai, Eisai Limited, Eli Lilly, Exelixis, Faron Pharmaceuticals Ltd, Forma Therapeutics, GamaMabs, Genentech, GlaxoSmithKline, H3 Biomedicine, Hoffmann La Roche Ag, ImCheck Therapeutics, Innate Pharma, Institut De Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin Pharm. Dev, Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular Partners Ag, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology Nv, Oncoethix, Oncopeptides, Orion Pharma, Ose Pharma, Pfizer, Pharma Mar, Pierre Fabre, Medicament, Roche, Sanofi Aventis, Seattle Genetics, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, and Xencor, research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Onxeo, Pfizer, Roche, and Sanofi, and nonfinancial support (drug supplied) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Medimmune, Merck, NH TherAguiX, Onxeo, Pfizer, and Roche. A. Le Cesne reported personal fees from PharmaMar and Bayer outside the submitted work. No disclosures were reported by the other authors.

PY - 2021/4/1

Y1 - 2021/4/1

UR - http://www.scopus.com/inward/record.url?scp=85104871504&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-0041

DO - 10.1158/1078-0432.CCR-21-0041

M3 - Letter

C2 - 33795374

AN - SCOPUS:85104871504

SN - 1078-0432

VL - 27

SP - 2120

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 7

ER -